ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

DARE Dare Bioscience Inc

0.3155
0.0182 (6.12%)
After Hours
Last Updated: 18:10:23
Delayed by 15 minutes

Period:

Draw Mode:

Volume 436,098
Bid Price 0.2789
Ask Price 0.3155
News -
Day High 0.29

Low
0.27

52 Week Range

High
1.10

Day Low 0.28
Company Name Stock Ticker Symbol Market Type
Dare Bioscience Inc DARE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0182 6.12% 0.3155 18:10:23
Open Price Low Price High Price Close Price Prev Close
0.29 0.28 0.29 0.286 0.2973
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
720 436,098 $ 0.2873415 $ 125,309 - 0.27 - 1.10
Last Trade Time Type Quantity Stock Price Currency
18:36:15 30 $ 0.305 USD

Dare Bioscience Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
28.58M 98.56M - 2.81M -30.16M -0.31 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Dare Bioscience News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No DARE Message Board. Create One! See More Posts on DARE Message Board See More Message Board Posts

Historical DARE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.460.48010.280.2854781,248,306-0.1445-31.41%
1 Month0.4990.55990.280.3540183488,855-0.1835-36.77%
3 Months0.32160.58990.280.4271573450,163-0.0061-1.90%
6 Months0.440.58990.270.3712106510,714-0.1245-28.30%
1 Year1.001.100.270.5037629381,091-0.6845-68.45%
3 Years1.532.510.271.641,828,276-1.21-79.38%
5 Years1.023.850.271.661,479,770-0.7045-69.07%

Dare Bioscience Description

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream.

Your Recent History

Delayed Upgrade Clock